According to the FDA, there have been 3 new cases of a potentially deadly brain infection linked to Tysabri, a multiple sclerosis drug. Since mid-2006, 13 cases of progressive multifocal leukoencephalopathy (PML) have been reported with Tysabri. PML is a rare infection, but the longer patients continue using Tysabri, they appear to be at an increased risk for developing PML. Biogen Idec Inc. and Elan Corp. PLC market Tysabri for treating multiple sclerosis and Crohn’s disease. Tysabri was introduced to the market in 2004 and then removed in 2005, following reports of PML. In July 2006, Tysabri was reintroduced.
If you or a family member has developed PML while using Tysabri, contact Sheller, P.C., to discuss your legal rights. Sheller lawyers are investigating potential litigation for people injured by Tysabri. Sheller, P.C. has a long history of successfully representing individuals and classes of people who have been injured by pharmaceuticals.
The Legal Examiner and our Affiliate Network strive to be the place you look to for news, context, and more, wherever your life intersects with the law.
Comments for this article are closed.